Plain-English translation of NCT05200260 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing the best timing for surgery combined with two types of maintenance therapy — or PARPi (olaparib) — in women newly diagnosed with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma. Researchers want to know whether it's better to have surgery first and then chemotherapy, or chemotherapy first and then surgery, followed by long-term treatment with the medication to help keep the cancer from coming back.
Doctors aren't yet certain about the optimal order of surgery and chemotherapy for advanced ovarian cancer, and adding maintenance therapy afterward may help patients live longer and stay cancer-free. This trial aims to find the best approach to give women the greatest benefit.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two treatment plans: either surgery first (within 3 weeks) followed by chemotherapy and long-term medication, or chemotherapy first (3 cycles) followed by surgery and then additional chemotherapy and long-term medication. In either case, you'll receive at least 6 cycles of chemotherapy total, and then continue with the medication (based on your genetic test results) for as long as it is helping. You'll have regular visits with your care team to monitor your response to treatment and manage any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China